NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Very well said and presented in exactly the right context Kabunushi!

This has always been my understanding, that OS was very important for IO, and that the longer the period outstanding, the more likely that we would see an ongoing benefit for those patients who were benefitted the most. But any of us just saying that is easily critiqued here by those who take the opposite, most aggressive stance. Presenting it in the context of the ARGS trial, and with regard to what they actually said, is extremely clarifying and very important. Thanks for that fantastic post!